期刊
PLOS BIOLOGY
卷 1, 期 3, 页码 385-396出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pbio.0000059
关键词
-
资金
- NCI NIH HHS [R24CA83084, R24 CA083084, R01 CA082328, U01 CA084292, CA-84292, R01 CA-82328, R01 CA137050] Funding Source: Medline
- PHS HHS [92629] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA137050, U01CA084292, R01CA082328, R24CA083084] Funding Source: NIH RePORTER
Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of Caps at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: pten(hy/+) > Pten(+/-) > Pten(hyl-) (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten(Pc)) mutants. In addition, we have generated and comparatively analyzed two distinct Pten(pc) mutants in which Pten is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects key downstream targets such as Akt, p27(Kip1), mTOR, and FOXO3. Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据